UNSPSC 51171717: Mebiquine

This classification denotes an antidiarrheal agent with the molecular formula C10H10BiNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DBE10Q8QF6, chemically known as quinoline, 8-((dihydroxybismuthino)oxy)-6-methyl- but generally known as mebiquine, which bears US NIH Compound Identifier 16683098. European Medicines Agency schedules Mebiquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08665MIG. The term MEBIQUINE is an International Non-Proprietary Name.

UNSPSC 51171717 Mefloquine, a Commodity code, nominally refers to a specific antimalarial pharmaceutical, but recent state and local procurement activity under this code shows a mismatch with that narrow product scope. The three most recent opportunities tagged to this code comprise offender drug testing services, a therapeutic pharmacy initiative market assessment, and a multistate cooperative purchasing contract for generic pharmaceuticals and over-the-counter products—none of which involve mefloquine specifically. State and local procurement systems appear to be using this code as a catch-all for pharmaceutical-adjacent services and commodity contracting rather than for procurement of the named drug itself. The issuing bodies include county criminal justice departments, state health and human services agencies, and multistate cooperative purchasing alliances serving state and local facilities across multiple jurisdictions.

Geographic activity centers on Texas and Minnesota. Collin County Community Supervision and Corrections Department in Texas posted an RFP for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026. The Texas Health and Human Services Commission issued a Request for Information on April 3, 2026 to explore direct-to-manufacturer prescription program capabilities without formal evaluation criteria or award values. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and DSCSA standards. The code shows minimal relevance to mefloquine procurement and appears underutilized or misapplied in recent state and local sourcing activity.